4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with debrisoquin in 2 studies
Studies (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Trials (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Recent Studies (post-2010) (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Studies (debrisoquin) | Trials (debrisoquin) | Recent Studies (post-2010) (debrisoquin) |
---|---|---|---|---|---|
70 | 12 | 9 | 890 | 89 | 17 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bertilsson, L; Dahl, ML; Ekqvist, B; Llerena, A | 2 |
2 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and debrisoquin
Article | Year |
---|---|
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
Topics: Chromatography, High Pressure Liquid; Debrisoquin; Haloperidol; Humans; Hydroxylation; Oxidation-Reduction; Phenotype | 1992 |
Genetic factors in the metabolism of haloperidol.
Topics: Debrisoquin; Half-Life; Haloperidol; Humans; Hydroxylation; Phenotype | 1992 |